Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
DALLAS/FORT WORTH, Texas, Nov. 07, 2017 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics, will present a company overview at the upcoming Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 4:15 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
[email protected]
Sarah McCabe
Vice President
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
